US 12,433,854 B2
Methods and compositions for preventing or treating calciphylaxis
James A. Tumlin, Lawrenceville, GA (US); Paul L. Darke, Hingham, MA (US); and John M. Rudey, New York, NY (US)
Assigned to Epizon Pharma, Inc., New York, NY (US)
Filed by Epizon Pharma, Inc., New York, NY (US)
Filed on Aug. 7, 2023, as Appl. No. 18/231,035.
Application 16/902,705 is a division of application No. 16/435,230, filed on Jun. 7, 2019, granted, now 10,736,858, issued on Aug. 11, 2020.
Application 18/231,035 is a continuation of application No. 17/349,663, filed on Jun. 16, 2021, granted, now 11,793,773.
Application 17/349,663 is a continuation of application No. 16/902,705, filed on Jun. 16, 2020, granted, now 11,065,212, issued on Jul. 20, 2021.
Claims priority of provisional application 62/682,794, filed on Jun. 8, 2018.
Prior Publication US 2024/0041794 A1, Feb. 8, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/122 (2006.01); A61K 31/047 (2006.01); A61K 31/22 (2006.01); A61K 31/366 (2006.01); A61K 31/40 (2006.01); A61K 31/405 (2006.01); A61K 31/47 (2006.01); A61K 31/505 (2006.01); A61P 3/14 (2006.01); A61P 13/12 (2006.01)
CPC A61K 31/122 (2013.01) [A61K 31/047 (2013.01); A61K 31/22 (2013.01); A61K 31/366 (2013.01); A61K 31/40 (2013.01); A61K 31/405 (2013.01); A61K 31/47 (2013.01); A61K 31/505 (2013.01); A61P 3/14 (2018.01); A61P 13/12 (2018.01)] 36 Claims
OG exemplary drawing
 
1. A method of treating calciphylaxis in a human subject in need thereof, the method comprising administering to the human subject a composition comprising menaquinol-7 (MKH2-7) thereby to treat calciphylaxis in the subject,
whereupon the administration of the MKH2-7 to the subject:
(i) decreases a plasma level of Highly Sensitive C Reactive Protein (hs-CRP) relative to the plasma level of hs-CRP prior to administration; or
(ii) increases a plasma level of osteoprotegerin relative to the plasma level of osteoprotegerin prior to administration.